Valuation: Supriya Lifescience Limited

Market Cap 69.4B 729M 654M 604M 547M 1.02B 1.04B 7.23B 2.88B 36.31B 2.73B 2.68B 115B P/E 2027 *
29.2x
P/E 2028 * 22.2x
Enterprise Value 69.4B 729M 654M 604M 547M 1.02B 1.04B 7.23B 2.88B 36.31B 2.73B 2.68B 115B EV / Sales 2027 *
6.99x
EV / Sales 2028 * 5.59x
Free-Float
28.72%
Yield 2027 *
-
Yield 2028 * -
1 day+1.33%
1 week-1.26%
Current month-9.26%
1 month-12.48%
3 months+2.05%
6 months+22.40%
Current year+14.74%
1 week 801
Extreme 801
879.2
1 month 801
Extreme 801
1,019.8
Current year 545.5
Extreme 545.5
1,085
1 year 545.5
Extreme 545.5
1,085
3 years 239.8
Extreme 239.8
1,085
5 years 170.15
Extreme 170.15
1,085
10 years 170.15
Extreme 170.15
1,085
Manager TitleAgeSince
Chief Executive Officer 35 01/08/2024
Chief Executive Officer 36 01/08/2024
Director of Finance/CFO - 23/01/2023
Director TitleAgeSince
Chairman 70 26/03/2008
Director/Board Member 41 01/06/2019
Director/Board Member 36 01/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.33%-1.26%+18.00%+244.07% 721M
+0.50%+0.36%+55.89%+129.96% 1,143B
+0.86%+4.50%+42.43%+86.15% 647B
-0.14%-1.07%+25.42%+105.85% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-4.97%+60.15%+37.06% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+2.94%+55.18%+72.74% 242B
+0.08%+1.72%+32.15%+107.78% 197B
Average +0.49%+1.07%+36.54%+93.17% 402.83B
Weighted average by Cap. +0.62%+0.71%+42.62%+89.04%

Financials

2027 *2028 *
Net sales 9.94B 104M 93.59M 86.53M 78.37M 146M 148M 1.03B 412M 5.2B 391M 383M 16.5B 12.42B 130M 117M 108M 97.95M 183M 185M 1.29B 515M 6.5B 489M 479M 20.63B
Net income 2.37B 24.91M 22.35M 20.66M 18.71M 34.96M 35.38M 247M 98.38M 1.24B 93.46M 91.49M 3.94B 3.12B 32.78M 29.41M 27.19M 24.63M 46.01M 46.56M 325M 129M 1.63B 123M 120M 5.19B
Net Debt - -
Projected Income Statement - Annual - Supriya Lifescience Limited
Logo Supriya Lifescience Limited
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in the manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 API products that offer remedies in therapeutic segments, such as antihistamines, analgesics, vitamins, anesthetics and anti-asthmatics, among others. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulfate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others. The Company has manufacturing facilities located in Maharashtra.
Employees
607
Date Price Change Volume
28/10/26 INR 862.25 +1.33% 199,541
27/10/26 INR 850.90 +2.14% 91,955
26/10/26 INR 833.05 +1.77% 90,442
23/10/26 INR 818.55 -2.12% 162,923
22/10/26 INR 836.25 -0.75% 112,881

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Supriya Lifescience Limited
  1. Stock Market
  2. Stocks
  3. SUPRIYA Stock